🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — October 14, 2026

Both filings in this window are Nasdaq listing-compliance disclosures, and both fall squarely within the Corporate Distress & Bankruptcy stream's delisting scope. AMASS Brands received a new Nasdaq notice for 30 consecutive business days below $1.00 (compliance deadline April 7, 2027), layered on top of a separate market value deficiency with a January 19, 2027 deadline, indicating compounding listing stress. Netcapital Inc. cured its bid-price deficiency but remains exposed to a more serious governance problem: late FY2026 10-K and Q1 FY2027 10-Q filings, prior financial statements declared unreliable for FY2022 through FY2025, auditor resignation, and a re-audit now under way with Adeptus Partners. The enriched period-over-period, insider, forward-looking, and capital-allocation fields are not populated for either filing, so quantitative trend analysis is not possible from this data; the conclusions rest on disclosed deficiencies and deadlines. The common theme is that sub-$1 trading and filing or reporting failures are the leading distress indicators for small-cap Nasdaq issuers, and both situations carry delisting risk that is only partly time-bounded.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — October 14, 2026

The 50-filing US/India regulatory stream for 2026-10-14 is dominated by control-transfer and restructuring events: several open offers under SEBI SAST (Mapro, South India Paper Mills, Avishkar Infra, Aar Shyam), multiple SPAC business combinations and deadline extensions (Pioneer/Green AI Cloud, FortuneX/WT Realty, Alpha Star, Future Vision II, Pine Tree), and a cluster of insolvency and distress events (Gangotri Textiles CIRP, BGR Energy with Rs.3,764.77 crore in bank defaults, Siti Networks RP change, Vas Infrastructure and AGS Transact CIRP timelines). Quantitative period-over-period data is sparse in this batch, but the available figures show sharp revenue growth from a tiny base at StageWise (+959%) alongside persistent losses, HFCL turnover up 19.3% YoY but still ~11% above FY2024 levels, and Brooks Laboratories' demerged manufacturing unit accounting for 96.66% of turnover. Listing-compliance stress is evident among SPAC and micro-cap names (AMASS Brands sub-$1 bid, Netcapital late 10-K/10-Q, Plum Acquisition IV holder-count deficiency). Strategic M&A is active in US mid-caps (Copart/ACV tender offer clearing HSR, Flex/EPC Power, Laurus/KRKA capital infusion), while fund-level activity includes Saba's 13D/A stake-building at Virtus NFJ, which is a discount-to-NAV activist setup. Most items are procedural or intra-group and carry low incremental market impact.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 14, 2026

Today's digest spans a mixed set of US SEC filings dominated by two large-cap bank/asset-manager reports (BlackRock and Bank of America), a major pending transocean/Valaris combination with a 9/10 materiality, and a Liquidia–United Therapeutics global settlement that reshapes a commercial franchise. The earnings picture is mixed rather than uniformly positive: BlackRock posted strong YoY growth (revenue up 19%, as-adjusted EPS up 38%) but a sequential GAAP decline driven by a $564M contingent consideration charge, while Bank of America's reported EPS fell YoY to $0.91 on a $1.2B regulatory settlement charge, with adjusted EPS of $1.08. Several small-cap and SPAC filers show financing stress or redemption pressure (Starry Sea extension and redemption fights, CytoMed Nasdaq deficiency, Integral Technologies widening deficit, Health In Tech equity line), a recurring theme that illustrates capital-access strain among micro-caps. Insider activity is light but directional: ASE's CAO sold ~$2.26M while Baozun's CEO bought ~$20K twice, a split signal. Forward-looking catalysts cluster in late October through December 2026, including the Transocean EGM (Nov 24), Sono Group EGM (Dec 11), Pioneer/Green AI Cloud closing (Q2 2027), and Accenture/SK hynix/ASML earnings-related events. Most filings are administrative or holdings-only, so day-to-day signal density is lower than the headline names suggest.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 14, 2026

The 17 filings dated 2026-10-14 are almost entirely Form 4 insider transaction reports from two S&P 500 Consumer Discretionary constituents: AutoZone (16 filings) and DoorDash (1 filing). The AutoZone set is dominated by routine, neutral-sentiment equity grants (non-qualified stock options) awarded to a broad slate of officers, including the President & CEO, CFO, COO, and multiple SVPs, which signals standard compensation activity rather than a directional view on the business. The DoorDash filing is the only open-market-style transaction in the set: CFO Inukonda Ravi sold 1,017 Class A shares at $195.00 (~$198K) under a Rule 10b5-1 plan, retaining 217,911 shares, and this sale is the sole negative-sentiment item. No period-over-period financial comparisons, guidance statements, M&A details, or capital allocation disclosures were present in the enriched data, so this digest cannot quantify revenue, margin, or balance-sheet trends. The market implication is limited: the day's filings are low-materiality compensation and pre-planned selling, and the main analytical value lies in noting the absence of fundamental catalysts rather than in directional signals.

17 high priority 17 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 14, 2026

Five SEC filings dated 2026-10-14 cover three S&P 500 healthcare constituents: Pfizer, Danaher, and Medtronic. The dominant development is Medtronic's completed exchange offer for MiniMed Group, which expired October 9, 2026, was oversubscribed, and was prorated at 18.289133%, leaving Medtronic with no remaining MiniMed stake after exchanging 55,032,401 Medtronic ordinary shares for 252,813,348 MiniMed shares. Insider activity is limited to routine or administrative transactions: Pfizer's CEO received a small phantom stock award (~$2.01K), while Danaher's Chairman of the Executive Committee and Chairman each disposed of 500,000 common shares to the issuer. The filings supply no period-over-period financial metrics, forward guidance, or capital allocation figures, so trend analysis and valuation comparisons cannot be completed from this batch. Overall sentiment is neutral across all five filings, and the most material items are the Medtronic transaction disclosures (materiality 7/10). Investors should treat the Danaher share dispositions as a governance and liquidity item to verify rather than a clear directional signal.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — October 14, 2026

Across this 20-filing SEC stream (period ending 2026-10-14, with 13 newly published and 7 for context), the dominant theme is financial stress among micro-cap and shell-style issuers, offset by a handful of larger filers showing genuine operating momentum. Of the filings, roughly half are negative or mixed with stockholders' deficits, going-concern-style liquidity dependence on related-party loans, and widening losses (e.g., Elventix, Jubilant Flame, Jingbo, Mobile Global Esports, Ankam, CytoDyn). On the positive side, Winmark (Q3 revenue +23.2% YoY, net income +6.1%), Aircastle (Q2 revenue +24.4% YoY, net income +21.1%), Sono-Tek (six-month net income +21.9%, operating cash inflow of $3.1M) and Comtech (Adjusted EBITDA up to $20.6M from $16.4M, gross margin 38.9% vs 31.6%) show real operating leverage. A notable pattern is that revenue growth is frequently not converting to earnings: Elite Express (+20.9% revenue, but net loss widened to $760K on a $1.0M opex surge), Ekso Bionics (+148% revenue, but net loss $(42.5)M driven by discontinued operations and stock-based compensation) and Surge Components (+4.6% nine-month sales, net income -8.7%). Liquidity is the most critical risk: several issuers are funding operations with related-party notes or convertible financing, and CytoDyn's $98.1M stockholders' deficit and $12.3M extinguishment loss highlight dilution risk. Market implication: favor quality of earnings and cash conversion over headline revenue growth in this cohort.

20 high priority 20 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 14, 2026

This digest covers 12 US SEC filings, all dated October 14, 2026, and centers on proxy statements (DEFM14A, DEF 14A) rather than executive pay disclosures. The stream focus is Executive Compensation Insights, and most filings present governance mechanics, shareholder votes, and merger or extension votes without compensation tables, so the enriched period-over-period, insider, and capital allocation fields are largely absent from the excerpts provided. The dominant theme is corporate restructuring and shareholder approval events: two large-cap transactions (Transocean/Valaris and Bowhead/American Family) and two SPAC deadline extensions (FACT II, Mountain Crest V) require holder votes in November 2026. Quantitative highlights include Atlassian's fiscal 2026 revenue up 26% y/y to $6.6 billion with Cloud revenue at $4.4 billion, Entera Bio's roughly $275 million private placement, and Valaris pro forma contract drilling revenue of $3,052 million for the six months to June 30, 2026. Governance themes include reverse split and dilution authority at Amesite, equity plan share increases at Entera Bio and Wave Life Sciences, and presiding-director and independence determinations at the Transcontinental/American Realty pair. Most filings are scheduled for November 10 to December 10, 2026 votes, so the near-term calendar is dense.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 14, 2026

This IPO Pipeline stream covered a single US SEC filing on 2026-10-14, a very quiet session. The only filing is Tattvance Corp's S-1 for 5,000,000 shares at a fixed $0.06 per share on a self-underwritten, best-efforts, no-minimum basis. The company is a pre-revenue Wyoming development-stage digital platform for the tattoo industry, with its flagship AI Tattoo Generator not yet commercially available and its website completed only on September 3, 2026. No period-over-period comparisons exist because the company has no operating history, so there are no cross-company trends or sector aggregates to report. The central development is a control change on September 24, 2026, when the founder sold all 2,000,000 of her shares to CEO Lukasz Dziedzic, who would hold 100% if nothing sells and about 28.57% if the full offering closes. The offering can close with zero proceeds, and no market maker has committed to quote the stock. Materiality is low (4/10) and sentiment is negative, so this is a monitoring item rather than an actionable investment idea.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — October 14, 2026

Both filings in this window concern Nasdaq listing-compliance matters rather than SEC trading suspensions per se, but they fall within the stream's Delisting and Regulatory Halt scope. AMASS Brands received a Nasdaq notice on October 9, 2026 for 30 consecutive business days below $1.00 (Rule 5450(a)(1)), with a compliance deadline of April 7, 2027, and it also carries a separate market value deficiency with a January 19, 2027 deadline. Netcapital Inc. regained bid-price compliance on October 7, 2026 after 10 consecutive business days at or above $1.00, but remains non-compliant with Rule 5250(c)(1) for late FY2026 10-K and Q1 FY2027 10-Q filings, with a compliance plan due October 23, 2026. The Netcapital situation is the more severe governance story: its FY2022 through FY2025 financial statements were declared unreliable, its prior auditor resigned, and a re-audit of FY2022 through FY2026 is underway. Enriched period-over-period, insider, forward-looking, and capital-allocation fields were not populated for either filing, so quantitative trend analysis is not possible from this data. The dominant theme is that sub-$1 price and filing-delinquency issues are colliding, creating delisting pathways that investors should track against specific dates.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — October 14, 2026

Across the 23 filings in the USA Executive & Director Changes stream (17 new, 6 contextual), the dominant theme is governance renewal: board refreshes with audit/finance expertise (Lisata, Compass, XTI, Jackson Financial, Enliven, Andersen Group), CEO and CFO successions (Verastem, PC Connection, Comtech, Mattel), and a cluster of C-suite departures at small and mid-cap names. The only filing with quantified period-over-period performance is State Street, which reported Q3 2026 diluted EPS of $3.69 (+33% YoY) and revenue of $4.0B (+13% YoY, -1% QoQ), but with mixed underlying detail: Other fee revenue fell 29% YoY and QoQ, FX trading services fell 14% QoQ, and CET1 declined 0.3 points YoY to 11.0%. Insider and compensation signals are noteworthy: Yext's 11M-share performance-based CEO option with 14 escalating price hurdles ($21 to $88.08) signals a long-dated conviction bet, while Alector's option repricing and Mattel's enhanced CEO change-in-control protections reflect retention-driven compensation design. The most material distress signals sit in Bubblr Inc., which is operating under a court-appointed receiver, with its CRO and a director resigning in early October. Several enriched financial fields (period comparisons, guidance, valuations) are empty for most filings, so the analytical edge here is primarily qualitative governance and timing.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 14, 2026

Across the 23 filings for the USA Board Room Changes stream (all dated 2026-10-14 window), the dominant theme is leadership reshuffling rather than financial performance: at least 10 filings involve CEO, CFO, CMO, CTO, CRO, CCO or General Counsel changes, director appointments, or board expansions. Only one filing (State Street) carries substantive period-over-period financials, and it is mixed: diluted EPS up 33% YoY to $3.69 and revenue up 13% YoY, but Other fee revenue fell 29% YoY and QoQ, FX trading services fell 14% QoQ, and CET1 slipped 0.3 pp YoY to 11.0%. Most other filings report no quantitative performance data, so the signal in this stream comes from governance quality, succession planning and transition risk. The most material governance developments are Verastem's planned CEO succession (Bailey replacing Paterson effective January 1, 2027), Comtech's CFO and CLO transitions tied to the Gilat sale of its Satellite & Space segment, and the court-appointed receivership at Bubblr where the Receiver is exercising board powers and officers are resigning. Director appointments skew toward experienced audit, CFO and life-science operators (Farrow at Lisata, Templin at Jackson, Ball at Enliven, Hsiao at Compass), which is a constructive governance pattern. Compensation design is also a recurring theme, with Yext's 11M-share performance option, Mattel's CEO severance raised to 2.99x with a 280G gross-up, and Alector's underwater option repricing. Overall, the stream reads as a mix of planned succession and governance strengthening against a small cluster of distressed or abrupt departures.

23 high priority 23 total filings
· daily

USA Insider Trading Pulse — October 14, 2026

The 50 Form 4 filings dated 2026-10-14 are almost entirely insider-transaction disclosures, and the data carries no period-over-period comparisons, forward-looking guidance, or capital allocation fields, so trend analysis is limited to transaction-level observations. Activity splits into three clusters: routine compensation and director award grants (CACI director exercises/RSU conversions, Procter & Gamble director stock awards at 1,438 shares each, Alliant Energy deferred stock unit grants at $65.85, Commercial Metals executive vesting with tax withholding at $63.89), open-market sales under 10b5-1 plans (Intapp, Ferguson, MSCI, Castle Biosciences, Aeluma, Core Scientific), and a small number of open-market purchases signaling insider conviction (Borr Drilling director Troim buying 1.5M shares at $4.93, roughly $7.4M; Terrestrial Energy CEO Irish buying 16,900 shares at $3.01; Baozun CEO Qiu buying about 11,800 ADS in total at roughly $3.40; Beyond Air 10% owner Lin buying at $2.21). The largest single open-market sale is Aeluma CEO Klamkin selling 100,000 shares at $10.53 (about $1.05M) under a 10b5-1 plan, and the largest insider sale by dollar value is ASE Technology's Uang selling 3,000 shares at $752 (about $2.26M). Net, the day's pattern leans toward modest selling by executives with a few meaningful buys, with no evidence of distress-driven selling at scale. Scheduled events, pledge disclosures, and holdings-change ratios are not present in the data supplied.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 14, 2026

This M&A and takeover digest covers 12 filings dated 2026-10-14, of which 9 are new and 3 are context. The dominant theme is SPAC activity: Pioneer Acquisition I (Green AI Cloud, $300M pre-money), FortuneX (WT Realty, fixed $525M equity value), Alpha Star (extension to Dec 2027), Pine Tree ($100M IPO), and Future Vision II (monthly extension loans) show the SPAC cohort still active but reliant on repeated extensions and sponsor-funded trust top-ups, with redemption risk embedded in each. Clear Channel's ~$6.2B take-private by Mubadala Capital closed with a CEO change, while Flex completed the EPC Power acquisition ahead of its planned Q1 2027 Axiom spin-off, the clearest strategic-simplification signal in the set. Financing stress is visible at SKYX, which took on $8.5M of 12% first-lien secured debt to close the Deako merger, and at CleanCore/ZONE, where pro forma continuing operations have no revenue and a $(40.1)M operating loss driven largely by digital-asset fair-value losses. Eton's LIBERVANT license lacks disclosed economics, and StageWise shows high percentage revenue growth off a tiny base alongside a going-concern warning. Net: deal flow is real but heavily dependent on extensions, financing and disclosure that often omits price or terms.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 14, 2026

The overnight SEC filing set for 2026-10-13 to 2026-10-14 is dominated by insider Form 4 activity (Zoetis phantom stock awards, Eagle Nuclear equity grants, CID Holdco purchases, and several 10b5-1 sales), Schedule 13D/A amendments from Talos Energy's Slim family holding vehicle and Suncrete's Haymaker sponsor distributions, and equity-capital-markets activity including IPO and resale registrations (NuvOx, SPACCircle, VME Companies, Health In Tech). Quantitative period-over-period data is sparse in the provided enriched content; most 6-K and S-1 filings are cover or exhibit-referencing documents without reported financial results, so trend analysis is limited to insider holdings, share-count changes, and redemption metrics. The most material developments are Talos Energy's continued sell-down (8.94M shares sold over four days, with control-holder ownership still at 17.8%), the Starry Sea SPAC extraordinary meeting postponement with roughly 74.5% of public shares tendered for redemption, and Health In Tech's Yorkville SEPA with discount-priced advance shares that introduce dilution risk. Nasdaq bid-price compliance dynamics appear in both CytoMed (deficiency, April 2027 cure deadline) and Nature Wood Group (regained compliance), highlighting divergent small-cap listing outcomes. Overall, the overnight tape leans toward supply-side pressure (insider and sponsor selling, SPAC redemptions, dilutive financing) rather than fundamental upside.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — October 13, 2026

This period contains 5 FDA approvals on October 7-8, 2026, comprising 0 NMEs, 0 biosimilars (as labeled in the source data), 1 label expansion, and 4 other approval actions classified as fallback pathway approvals; the single bullish signal is the OLANZAPINE (WELTRUZA) label expansion from TEVA NEUROSCIENCE INC. The approval mix is dominated by generic-type and fallback actions rather than novel therapeutics, so there is no dominant therapeutic area cluster: the drugs span neuropsychiatry (pitolisant, olanzapine), urology (mirabegron), infectious disease (fidaxomicin), and cardiovascular/diuretic (hydrochlorothiazide). Highest-conviction signal is the TEVA NEUROSCIENCE olanzapine label expansion (WELTRUZA), which extends an existing franchise without requiring new-molecule investment. Key watch item is the classification inconsistency in the source data: four actions are labeled 'biosimilar' for small molecules (pitolisant, mirabegron, fidaxomicin, hydrochlorothiazide), which is pharmacologically atypical and should be verified against FDA records before any investment conclusion is drawn. Commercial data is NOT_DISCLOSED across all five approvals.

5 total filings
· daily

Big Pharma Approvals — October 13, 2026

This October 13, 2026 digest covers four FDA approvals, all classified as label expansions by the fallback classification (0 NME, 0 biosimilar, 0 label expansion in the typed mix, 4 other), with all four carrying bullish signals at strength 5/10 and materiality 5/10. The approvals span three sponsors: Amgen Inc (evolocumab/REPATHA), Genentech Inc (atezolizumab/TECENTRIQ and atezolizumab with hyaluronidase-tqjs/TECENTRIQ HYBREZA), and AstraZeneca AB (budesonide, glycopyrrolate, and formoterol fumarate/BREZTRI AEROSPHERE). The dominant theme is oncology concentration at Genentech, with two atezolizumab-related approvals, alongside cardiovascular (Amgen) and respiratory (AstraZeneca) approvals. The highest-conviction signal is the Genentech atezolizumab franchise, where two approvals in the same period point to continued lifecycle investment, including a subcutaneous formulation (HYBREZA) that may support patient convenience and competitive positioning. Commercial data (peak sales, exclusivity, pricing power, market position) is NOT_DISCLOSED for all four approvals, so the analysis cannot quantify revenue impact; the primary watch item is that label expansions of established brands carry limited incremental-revenue visibility without indication size and payer data.

4 total filings
· daily

Orphan Drug Approvals — October 13, 2026

This digest covers a single FDA action in the period October 13, 2026 (window: October 13, 2026 to October 13, 2026), in the Orphan Drug Approvals stream. The approval mix is 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other action, so no new molecular entity or biosimilar entry signal is present this period. The sole event is a label expansion-type action for evolocumab (REPATHA) from Amgen Inc., classified internally as a fallback approval type and carrying a bullish signal at strength 5/10 and materiality 5/10. Because the event is moderate in strength and materiality and no commercial data (peak sales, exclusivity, pricing power, market position) is disclosed, conviction is limited. There is no therapeutic area clustering to report from a single approval. The key watch item is the absence of disclosed indication, sizing, and label detail, which prevents an assessment of whether this action meaningfully expands Repatha's addressable population.

1 total filings
· daily

New Drug Approvals (Original) — October 13, 2026

This period (October 13, 2026, reporting window of 6 approvals) contains zero NME approvals, zero biosimilar approvals in the stream-classified sense, and zero label expansions by the mix classification, with all six events categorized as 'Other' under the FALLBACK approval type. The four neutral and two bullish signals (5/10 strength and materiality across the board) reflect limited commercial differentiation, with Peak Sales, Exclusivity, Pricing Power, and Market Position all reported as NOT_DISCLOSED for every approval. The highest-conviction signal is the TEVA NEUROSCIENCE INC OLANZAPINE (WELTRUZA) label expansion and the ASTRAZENECA AB BREZTRI AEROSPHERE label expansion, both bullish, as established franchise label extensions carry lower execution risk than new entrants. The dominant therapeutic theme is respiratory and CNS/psychiatry, with BREZTRI in COPD and OLANZAPINE in neuropsychiatry, though the sample is too small to constitute a sector trend. The key watch item is the labeling of several generic-style approvals (PITOLISANT, MIRABEGRON, FIDAXOMICIN, HYDROCHLOROTHIAZIDE) as biosimilars, which is inconsistent with their small-molecule chemistry and should be verified against FDA Orange Book and Purple Book records before any investment conclusion is drawn.

6 total filings
· daily

New Federal Contractors — October 13, 2026

Three new federal contract awards totaling $65,819,086 were reviewed for the period October 13, 2026, though all three awards are dated 2023 through 2026 and none is defense-related (0 of 3), making this a purely civilian-agency digest. Awards span GSA (Messer Construction Co, $22,581,570), HHS/CDC (Digital Management LLC, $21,908,995), and USDA Forest Service (Perimeter Solutions LP, $21,328,521), so no single agency dominates and the theme is diversified civilian spending rather than a unified sector trend. The highest-conviction item is the Perimeter Solutions USDA award, which carries the highest materiality score (4/10) and a 2026 performance window tied to wildfire retardant demand, though its revenue weight to the company is undisclosed. The primary watch item is that Digital Management LLC and Messer Construction Co have period-end and option-exercise dates in 2026 and 2027 respectively, and none of the three recipients' public-company status or total revenue is established in the data, which limits investability conclusions. Average signal strength is 3.3/10, so the set supports monitoring rather than position changes.

3 total filings
· daily

Significant Contract Modifications ($10M+) — October 13, 2026

Three significant contract modifications totaling $65,819,086 were reported for the October 13, 2026 window, with zero defense-related awards and the entire stream sitting in civilian agencies: GSA ($22,581,570 to Messer Construction Co), HHS/CDC ($21,908,995 to Digital Management LLC), and USDA Forest Service ($21,328,521 to Perimeter Solutions LP). The dominant theme is civilian facilities, IT hosting, and wildfire-suppression supply rather than defense modernization, and all three awards were competed on a full-and-open basis with firm-fixed-price pricing. Average signal strength was 3.3/10 and every contract was rated neutral, so no bullish or bearish call is supported by this data alone. The highest-materiality item is the Perimeter Solutions USDA award, which has the largest share of unspent obligation (about $13.5M remaining through 2026) and is the most useful watch item. The key risk is that recipient financials are not disclosed, so materiality to any listed equity cannot be established from these records.

3 total filings